DexCom earnings beat by $0.03, revenue topped estimates
In a recent transaction, Donald Dwyer, the Chief Business Officer of Vivani Medical (TASE:BLWV), Inc. (NASDAQ:VANI), acquired 4,000 shares of the company’s common stock on April 1, 2025. The shares were purchased on the open market at a price of $1.025 per share, amounting to a total transaction value of $4,100. The purchase comes as the stock trades near its 52-week low of $1.00, with InvestingPro data showing analysts setting a $4.00 price target for the shares. Following this purchase, Dwyer holds a total of 55,000 shares directly. This transaction highlights Dwyer’s continued investment in Vivani Medical, a company operating in the electromedical and electrotherapeutic apparatus industry. With a market capitalization of $62.2 million, the company maintains strong liquidity with a current ratio of 3.41. InvestingPro analysis reveals 7 additional key insights about VANI’s financial health and growth prospects.
In other recent news, Vivani Medical has secured $8.25 million through a private placement to advance its drug implant development projects. The funds will primarily support the development of NPM-139, a semaglutide implant for chronic weight management, and NPM-115, an exenatide implant. Vivani Medical also reported promising preclinical results for NPM-139, showing significant weight loss in a study with healthy rats, suggesting potential once or twice-yearly dosing. H.C. Wainwright analyst Yi Chen maintained a Buy rating with a $4.00 price target for Vivani Medical, citing positive preclinical data for NPM-139 as a key factor. Furthermore, Vivani Medical announced the successful administration of its GLP-1 (exenatide) implant in the LIBERATE-1 clinical trial, which achieved full enrollment within four weeks. The trial aims to assess the safety, tolerability, and pharmacokinetics of the NPM-115 implant, with top-line results expected in mid-2025. Vivani’s CEO, Adam Mendelsohn, expressed optimism about the potential of their NanoPortal technology to improve medication adherence. The company plans to leverage Australian R&D incentives to offset trial costs, with data expected to be acceptable to the U.S. FDA and other regulatory authorities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.